Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-PLACE: MOR202 in anti-PLA2R antibody-positive membranous nephropathy
NL-OMON49767Phase 2Withdrawn
- Sponsor
- MorphoSys AG
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of felzartamab in membranous glomerulonephritis (MGN) (2 cohorts), sponsored by MorphoSys AG. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Planned start Jul 2019; status: withdrawn.
02
Drugs
felzartamab
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on NL-OMON49767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49767.